







an Open Access Journal by MDPI

# Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

Guest Editors:

#### Dr. Luca Miele

Division of Internal Medicine, Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy

### Prof. Helen L. Reeves

Northern Institute for Cancer Research Paul O'Gorman BuildingMedical School, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK

Deadline for manuscript submissions:

closed (30 September 2021)

# **Message from the Guest Editors**

Dear Colleagues,

Hepatocellular carcinoma (HCC) is becoming one of the most common cancers in world and is a leading cause of cancer-related deaths. The prevalence of non-alcoholic fatty liver disease (NAFLD) has risen rapidly and is now a frequent cause of chronic liver disease and HCC (NAFLD-related HCC). Currently, despite ongoing studies (including omics, genetic, serum, microbiota markers), there are no clinically useful biomarkers that can effectively identify the subjects at the greatest risk of developing NAFLD-HCC, nor those that aid in treatment stratification.

Within this Special Issue, we aim to bring contributions that will direct future research strategies, aiding the collaborative research required for the future development of clinically relevant guidelines. Topics covered will include epidemiology; environmental and individual risk factors; genetic and molecular mechanisms; diagnostic techniques (imaging and other omics biomarkers); treatments (interventional radiology, surgery, transplantation, innovative drugs and immunotherapy); prevention and surveillance policies; personalized and multidisciplinary team approaches.

Prof. Luca Miele Prof. Helen L. Reeves













an Open Access Journal by MDPI

### **Editor-in-Chief**

### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**